title: [Comparative study of alpha-lipoic acid and mexidol effects on affective status, cognitive functions and quality of life in diabetes mellitus patients].
abstract: Short-term, prospective placebo-controlled simple blind randomized study of the effects of alpha-lipoic acid and mexidol on the dynamics of affective status disorders, cognitive functions, and quality of life in parallel with changes in carbohydrate metabolism and lipidemia has been conducted in diabetic patients. It is established that two-week administration of alpha-lipoic acid (600 mg once a day, i.v.) and mexidol (300 mg once a day, i.v.) reduced hyperglycemia by 13.00 with simultaneous decrease of depressive "feelings of guilt". In case of mexidol, these effects were accompanied by positive "vitality" dynamics established with SF-36 questionnaire and reflecting improvement in patients' quality of life. Additionally, course administration of alpha-lipoic acid increased attention as studied with Schulte tables. Favorable psychotropic effects of alpha-lipoic acid and mexidol were unrelated to changes in lipidemia and "lipid peroxidation - antioxidant protection" system indicators.
authors.forename: I A
authors.initials: IA
authors.lastname: Volchegorskiĭ
authors.forename: L M
authors.initials: LM
authors.lastname: Rassokhina
authors.forename: M I
authors.initials: MI
authors.lastname: Koliadich
authors.forename: M I
authors.initials: MI
authors.lastname: Alekseev
mesh_terms: D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use; D001288:Attention / Q000187:drug effects; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D048909:Diabetes Complications / Q000188:drug therapy*; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000188:drug therapy / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010847:Picolines / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011446:Prospective Studies; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000627:therapeutic use; D011788:Quality of Life; D012426:Russia; D011795:Surveys and Questionnaires; D008063:Thioctic Acid / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000975:Antioxidants; D007004:Hypoglycemic Agents; D010847:Picolines; D010919:Placebos; D011619:Psychotropic Drugs; C070020:emoxypine succinate; D008063:Thioctic Acid